Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

9.64
-0.3100-3.12%
Post-market: 9.56-0.0806-0.84%19:58 EDT
Volume:1.35M
Turnover:13.19M
Market Cap:728.33M
PE:-9.10
High:10.20
Open:9.90
Low:9.55
Close:9.95
Loading ...

Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder

Benzinga
·
06 Mar

BRIEF-MindMed FY Net Income USD -108.679 Million

Reuters
·
06 Mar

MindMed FY Basic EPS USD -1.54

THOMSON REUTERS
·
06 Mar

MindMed FY Operating Expenses USD 103.916 Million

THOMSON REUTERS
·
06 Mar

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Business Wire
·
06 Mar

MindMed to Present at Leerink’s Global Healthcare Conference 2025

Business Wire
·
04 Mar

Press Release: MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Dow Jones
·
20 Feb

Mind Medicine (MNMD) Advances Groundbreaking LSD Treatment

TIPRANKS
·
06 Feb

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Dow Jones
·
05 Feb

Mind Medicine doses first patient in Panorama study

TIPRANKS
·
30 Jan

Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of Mm120 in Generalized Anxiety Disorder

THOMSON REUTERS
·
30 Jan

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Business Wire
·
30 Jan